Attention-deficit/hyperactivity disorder

Journal of Pharmacy Practice

Volumn 27, Issue 4, 2014, Pages 336-349

  Bokor, Gyula ^a   Anderson, Peter D ^a  

^a Taunton State Hospital   (United States)

Author keywords

ADHD; pediatrics; psychiatry; psychopharmacology; psychostimulants

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; AMPHETAMINE PLUS DEXAMPHETAMINE; ATOMOXETINE; DESIPRAMINE; DONEPEZIL; DOPAMINE; GUANFACINE; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORTRIPTYLINE; VENLAFAXINE; CENTRAL STIMULANT AGENT;

ACADEMIC FAILURE; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; CRIMINAL JUSTICE; DIFFERENTIAL DIAGNOSIS; DRUG THERAPY; FOLLOW UP; FRONTAL LOBE; GROUP THERAPY; HUMAN; INCIDENCE; JOB ACCOMMODATION; JOB PERFORMANCE; META ANALYSIS (TOPIC); NEUROBIOLOGY; NEUROFEEDBACK; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PSYCHOEDUCATION; RATING SCALE; SELF ESTEEM; SOCIAL PROBLEM; SUBSTANCE ABUSE; CHILD; METABOLISM; PATHOLOGY;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOPAMINE; FRONTAL LOBE; HUMANS; NOREPINEPHRINE;

EID: 84907199036     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014543628     Document Type: Article

References (162)

1. HurleyPJEmeR. ADHD and the criminal justice system: spinning out of control. https://www.ncjrs.gov/App/Publications/abstract.aspx?ID=208348. Accessed January 24, 2013.
2. Jaffe P. History and overview of adult ADD. In: Nadeau KG. A Comprehensive Guide to Attention Deficit Disorder in Adults: Research, Diagnosis, Treatment. 1995 ;: 3-17
3. Wender PH Attention Deficit Disorder in Adults. The Hyperactive Child, Adolescent, and Adult: Attention Deficit Disorder Through the Lifespan. New York, NY: Oxford University Press ; 1987: 117-140.
4. Diagnostic and Statistical Manual of Mental Disorders 5th edition. Washington, DC: American Psychiatric Association ; 2013: 31-86.
5. Disorders Usually First Diagnosed in Infancy, Childhood, or Adolescence. Diagnostic and Statistical Manual of Mental Disorders 4th edition. Washington, DC: American Psychiatric Association ; 1994: 37-121.
6. Sibley MH, Waxmonsky JG, Robb JA, et al. Implications for changes for the field: ADHD. J Learn Disabil. 2013 ; 46 ((1)). 34-42
7. Adler LA, Barkley RA, Wilens TE, et al. Differential diagnosis of attention deficit hyperactivity disorder and comorbid conditions. Prim Psychiatry. 2006 ; 13 (5 supp 3). 1-16
8. Epilepsy Foundation. Absence seizures. http://www.epilepsy.com/epilepsy/seizureence. Accessed January 28, 2013.
9. RobbAS. Differential diagnosis of ADHD in school-age children. http://www.medscape.com/viewarticle/544948-3. Accessed January 28, 2013.
10. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children - United States, 2003-2007. Access September 26, 2013 fromhttp://www.cdc.gov/mmwr/preview/mmwrhtml/mm5944a3.htm?s-cid=mm5944a3-w. Accessed February 9, 2013.
11. Rowland AS, Lesesne CA, Abramowitz AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002 ; 8 ((3)). 162-170
12. Thapar A, Cooper M, Eyre O, et al. What have we learnt about the causes of ADHD?. J Child Psychol Psychiatry. 2013 ; 54 ((1)). 3-16
13. Elia J, Sackett J, Turner, et al. Attention-deficit/hyperactivity disorder genomics: update for clinicians. Curr Psychiatry Rep. 2012 ; 14 ((5)). 579-589
14. Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. Hum Genet. 2009 ; 126 ((1)). 13-50
15. Salatino-Oliveira A, Genro JP, Chazan R, et al. Association of study of G1T1 gene with attention-deficit hyperactivity disorder in Brazilian children and adolescents. Genes Brain Behav. 2012 ; 11 ((7)). 864-868
16. Martinez-Levy GA, Benjet C, Perez-Molina A, et al. Association of the catechol-O-methyltransferase gene and attention deficit hyperactivity disorder: results from and epidemiological study of adolescents in Mexico City. Psychiatr Genet. 2013 ; 23 ((2)). 90-91
17. Braun JM, Kahn RS, Froehlich T, et al. Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ Health Perspect. 2006 ; 114 ((12)). 1904-1909
18. Bouchard MF, Bellinger DC, Wright RO, et al. Attention-deficit/hyperactivity disorder and urinary metabolites of organophosphate pesticides. Pediatrics. 2010 ; 125 ((6)). e1270 - e1277
19. Mill J, Petronis A. Pre- and peri-natal environmental risks for attention-deficit hyperactivity disorder (ADHD): the potential role of epigenetic processes in mediating susceptibility. J Child Psychol Psychiatry. 2008 ; 49 ((10)). 1020-1030
20. Kanarek RB. Artificial food dyes and attention deficit hyperactivity disorder. Nutr Rev. 2011 ; 69 ((7)). 385-391
21. Turner CA, Xie D, Zimmerman BM, et al. Iron status in toddlerhood predicts sensitivity to psychostimulants in children. J Attend Disord. 2012 ; 16 ((4)). 295-303
22. Kleinman RE, Brown RT, Cutter GR, et al. A research model for investigating the effects of artificial food colorings on children with ADHD. Pediatrics. 2011 ; 127 ((6)). 1575-1584
23. Weiss B. Synthetic food colors and neurobehavioral hazards: the view from environmental health research. Environ Health Perspect. 2012 ; 120 ((1)). 1-5
24. Nigg JT, Lewis K, Edinger T, et al. Meta-analysis of attention deficit/hyperactivity disorder or attention deficit/hyperactivity disorder symptoms, restriction diet, and synthetic food color additives. J Am Acad Child Adolesc Psychiatry. 2012 ; 51 ((1)). 86-97
25. Daley D, Birchwood J. ADHD and academic performance: why does ADHD impact on academic performance and what can be done to support ADHD children in the classroom?. Child Care Health Dev. 2010 ; 36 ((4)). 455-464
26. Stavrinos D, Biasini FJ, Fine PR, et al. Mediating factors associated with pedestrian injury in children with attention-deficit/hyperactivity disorder. Pediatrics. 2011 ; 128 ((2)). 296-302
27. Jerome L. Novice drivers with attention-deficit hyperactivity disorder. CMAJ. 2007 ; 176 ((12)). 1735
28. EmeRF. Attention Deficit/Hyperactivity Disorder and the Juvenile Justice System. https://www.ncjrs.gov/App/Publications/abstract.aspx?ID=245581. Accessed February 15, 2013.
29. Kousha M, Shahrivar Z, Alaghbard-Rad J. Substance use disorder and ADHD: is ADHD a particularly "specific" risk factor?. J Attend Disord. 2012 ; 16 ((4)). 325-332
30. Rooney M, Chronis-Tuscano A, Yoon Y. Substance use in college students with ADHD. J Attend Disord. 2012 ; 16 ((3)). 221-234
31. Tamm L, Adinoff B, Nakonezny PA, et al. Attention-deficit/hyperactivity disorder subtypes in adolescents with comorbid substance-use disorder. Am J Drug Alcohol Abuse. 2012 ; 38 ((1)). 93-100
32. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders?: findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997 ; 36 ((1)). 21-29
33. Weinstein A, Weizman A. Emerging association between addictive gaming and attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2012 ; 14 ((5)). 590-597
34. Investigating facets of personality in adult pathological gamblers with ADHD. Neuropsychiatry. 2012 ; 2 ((2)). 163-174
35. Weiss MD, Baer S, Allan BA, et al. The screens culture: impact on ADHD. Atten Defic Hyperact Disord. 2011 ; 3 ((4)). 327-334
36. Niedermeyer E, Naidu SB. Attention-deficit hyperactivity disorder (ADHD) and frontal-motor cortex disconnection. Clin Electroencephalogr. 1997 ; 28 ((3)). 130-136
37. Semrud-Clikeman M, Walkowiak J, Wilkinson A, et al. Executive functioning in children with asperger syndrome, ADHD-combined type, ADHD-predominately inattentive type and controls. J Autism Dev Disord. 2010 ; 40 ((8)). 1017-1027
38. Umhau JC, Trandem K, Shah M, et al. The physician's unique role in preventing violence: a neglected opportunity. BMC Med. 2012 ; 10: 146
39. Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry. 2008 ; 165 ((4)). 429-442
40. Cortese S, Castellanos FX. Neuroimaging of attention-deficit/hyperactivity disorder: current neuroscience-informed perspectives for clinicians. Curr Psychiatry Rep. 2012 ; 14 ((5)). 568-578
41. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain default network anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008 ; 1124: 1-38
42. Levy F. Dopamine vs. noradrenaline: inverted-U effects and ADHD theories. Aust N Z Psychiatry. 2009 ; 43 ((2)). 101-108
43. Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry. 1991 ; 25 ((2)). 277-283
44. Cools R. Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist. 2008 ; 14 ((4)). 381-395
45. HuntRD. Functional roles of norepinephrine and dopamine in ADHD. www.medscape.org/viewarticle/523887. Accessed February 18, 2013.
46. Cartford MC, Gould T, Bickford PC. A central role for norepinephrine in the modulation of cerebellar learning tasks. Behav Cogn Neurosci Rev. 2004 ; 3 ((2)). 131-138
47. Johansson J, Landgren M, Fernell E, et al. Altered tryptophan and alanine transport in fibroblasts from boys with attention-deficit/hyperactivity disorder (adhd): an in vitro study. Behav Brain Funct. 2011 ; 7 ( 40 ):
48. Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. Clin Psychol Rev. 2006 ; 26 ((4)). 379-395
49. Oades RD. Dopamine-serotonin interaction in attention-deficit hyperactivity disorder. Prog Brain Res. 2008 ; 172: 543-565
50. Sarter M, Paolone G. Deficits in attentional control: cholinergic mechanisms and circuitry-based treatment approaches. Behav Neurosci. 2011 ; 125 ((6)). 825-835
51. Knouse LE, Cooper-Vince C, Sprinch S, et al. Recent developments in the psychosocial treatment of adult ADHD. Expert Rev Neurother. 2008 ; 8 ((10)). 1537-1548
52. Knouse LE, Safren SA. Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. Psych Clin North Am. 2010 ; 33 ((3)). 497-509
53. Lofthouse N, Arnold LE, Hurt E. Current status of neurofeedback for attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2012 ; 14 ((5)). 536-542
54. Laird Knight L, Saklad JJ. Attention-deficit hyperactivity disorder. J Pharm Pract. 1990 ; 3 ((4)). 241-251
55. Sherwood DA, Rey JA. Pharmacological agents for the treatment of adult attention deficit hyperactivity disorder. J Pharm Pract. 2006 ; 19 ((6)). 336-341
56. American Academy of Pediatrics. http://pediatrics.aappublications.org/content/early/2011/10/14/peds.2011-2654. Accessed October 27, 2013.
57. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004 ; 113 ((4)). 754-761
58. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010 ; 10: 67
59. Devilbiss DM, Berridge CW. Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortical neuronal responsiveness. Biol Psychiatry. 2008 ; 64 ((7)). 626-635
60. Froehlich TE, Epstein JN, Nick TG, et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011 ; 50 ((11)). 1129-1139
61. Zhang CL, Feng ZJ, Liu Y, et al. Methylphenidate enhances NMDA-receptor response in medial prefrontal cortex via sigma-1 receptor: a novel mechanism of methylphenidate action. PLoS One. 2012 ; 7 ((12)). e51910
62. Package Insert methylphenidate. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=330e620f-4b7f-4101-91dd-feddb7a823ed. Accessed October 27, 2013.
63. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1995 ; 52 ((16)). 434-443
64. SurmanCB. Correct stimulant dose for adults; interactions between SSRIS and stimulants. Medscape Eduction. http://www.medscape.org/viewarticle/553351. Accessed February 28, 2013.
65. Liebrenz M, Hof D, Buadze A, et al. High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report. J Med Case Rep. 2012 ; 6 ((1)). 125
66. Nemoda Z, Angyal N, Tarnok Z, et al. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology. 2009 ; 57 (7-8). 731-733
67. UCB, Inc. Package insert Metacade CD. http://www.ucb.com/-up/ucb-com-products/documents/Metadate-CD-06-2013.pdf. Accessed October 27, 2013.
68. Package insert Ritalin LA. http://www.pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/ritalin-la.pdf. Accessed September 16, 2013.
69. Daytrana package insert. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2c312c31-3198-4775-91ab-294e0b4b9e7f. Accessed October 27, 2013.
70. Keating GM. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in adolescents: profile report. Drugs R D. 2012 ; 12 ((3)). 171-173
71. Novartis. Package insert Focalin. http://www.pharma.us.novartis.com/product/pi/pdf/focalin.pdf. Accessed October 27, 2013.
72. Novartis. Package insert Focalin XR. http://www.pharma.us.novartis.com/product/pi/pdf/focalinXR.pdf. Accessed October 27, 2013.
73. Hoffman BB, Lefkowitz RJ Goodman' and Gilman's The Pharmacological Basis of Therapeutics 9th edition. Hardman JG Limbird LE Molinoff PB Ruddon RW Goodman Gilman A, ed. New York, NY: McGraw-Hill ; 1996: 199-248.
74. Calipari ES, Ferris MJ. Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci. 2013 ; 33 ((21)). 8923-8925
75. Rothman RB, Baumann MH, Dersch CM, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and norepinephrine. Synapse. 2001 ; 39 ((1)). 32-41
76. Amedra Pharmaceuticals. Package insert dextroamphetamines. http://www.dexedrine.com/docs/dexedrine-PI.pdf. Accessed October 26, 2013.
77. Package insert Adderall. http://www.accessdata.fda.gov/drugsatfda-docs/label/2007/011522s040lbl.pdf. Accessed October 27, 2013.
78. Package insert Desoxyn. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a718c645-49c7-4a9c-a348-86874019134b. Accessed October 27, 2013.
79. Package insert Vyvanse. http://pi.shirecontent.com/PI/PDFs/Vyvanse-USA-ENG.pdf. Accessed October 26, 2013.
80. Madaan V, Koli V, Bestha DP, et al. Update on optimal use of lisdexamfetamine in the treatment of ADHD. Neuropsychiatr Dis Treat. 2013 ; 9: 971-983
81. Krishnan S, Montcrief S. Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies. Basic Clin Pharmacol Toxicol. 2007 ; 101 ((4)). 231-240
82. Kim D. Practical use and risk of modafinil, a novel waking drug. Environ Health Toxicol. 2012 ; 27 (e2012007). 7
83. Rugino T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat. 2007 ; 3 ((3)). 293-301
84. American Society of Health-System Pharmacists. http://www.ashp.org/menu/News/PharmacyNews/NewsArticle.aspx?id=2280. Accessed September 26, 2013.
85. Package Insert Modafinil. http://provigil.com/media/PDFs/prescribing-info.pdf.
86. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American heart association council on cardiovascular disease in the young congenital cardiac defects committee and council on cardiovascular nursing. Circulation. 2008 ; 117 ((8)). 2407-2423
87. American Heart Association. American Heart Association/American Academy of Pediatrics clarification statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving mediations for ADHD. http://newsroom.heart.org/news/american-academy-of-pediatrics-218228. Accessed October 26, 2013.
88. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and deaths in children exposed and unexposed to ADHD agents. Pediatrics. 2011 ; 127 ((6)). 1102-1110
89. Hill SL, El-Khayat RH. Electrocardiographic effects of methylphenidate overdose. Clin Toxicol (Phila). 2010 ; 48 ((4)). 342-346
90. Stiefel G, Begag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention deficit hyperactivity disorder. Drug Saf. 2010 ; 33 ((10)). 821-842
91. Klampfi K, Quattlander A, Burger R, et al. Case report: intoxication with high-dose of long-acting methylphenidate (Concerta) in suicidal 14-year-old girl. Atten Defic Hyperact Disord. 2010 ; 2 ((4)). 221-224
92. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr. 2002 ; 14 ((2)). 219-223
93. Safer DJ. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 1992 ; 2 ((4)). 279-290
94. Goldman RD. ADHD stimulants and their effect on height in children. Can Fam Physician. 2010 ; 56 ((2)). 145-146
95. Vitiello B. Understanding the risk of using medications for ADHD with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008 ; 17 ((2)). 459-474
96. Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010 ; 157 ((4)). 635-640
97. Kilgore BS, Dickinson LC, Burnett CR, et al. Alterations in cartilage metabolism by neurostimulant drugs. J Pediatr. 1979 ; 94 ((4)). 542-545
98. Ptacek R, Kuzelova H. ADHD and growth: anthropometric changes in medicated and on-medicated ADHD boys. Med Sci Monit. 2009 ; 15 (12). CR595 - CR599
99. Steiner H, Van Waes V. Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Prog Neurobiol. 2013 ; 100: 60-80
100. Sepulveda DR, Thomas LM, McCabe SE, et al. Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: preliminary analysis among college students. J Pharm Pract. 2011 ; 24 ((6)). 551-560
101. Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics. 2009 ; 124 ((3)). 875-880
102. Zosel A, Bartelson BB, Bailey E, et al. Characterization of the adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS°) system. J Amer Acad Child Adolesc Psychiatry. 2013 ; 52 ((2)). 196-204
103. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999 ; 104 ((2)). e20
104. Winters KC, Lee S, Botzet A, et al. A prospective examination of the association of stimulant medication history and drug use outcomes among community samples of ADHD youths. J Child Adolesc Subst Abuse. 2011 ; 20 ((4)). 314-329
105. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008 ; 165 ((5)). 597-603
106. Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: a prospective follow-up into adulthood. Am J Psychiatry. 2008 ; 165 ((5)). 604-609
107. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003 ; 111 ((1)). 97-109
108. Lambert NM, Hartscough CS. Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998 ; 31 ((6)). 533-544
109. Jankovic J. Tourette's syndrome. N Engl J Med. 2001 ; 345 ((16)). 1184-1192
110. Gadow KD, Nolan EE, Sprafkin J, et al. Tics and psychiatric comorbidity in children and adolescents. Dev Med Child Neurol. 2002 ; 44 ((5)). 330-338
111. Sandor P. Pharmacological Management of Tics in Patients with TS. J Psychosom Res. 2003 ; 55 ((1)). 41-48
112. Nass R, Bressman S. Attention deficit hyperactivity disorder and Tourette syndrome: what's the best treatment. Neurology. 2002 ; 58 ((4)). 513-514
113. Sussman J, Lorefice S, Gorman DA. Pediatric psychopharmacology update: psychostimulants and tics- past present and future. J Can Acad Child Adolesc Psychiatry. 2006 ; 15 ((3)). 143-144
114. Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009 ; 48 ((9)). 884-893
115. Bymaster FP, Katmer JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 ; 27 ((5)). 699-711
116. Ludolph AG, Udvardi PT, Schaz U, et al. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J of Pharmacol. 2010 ; 160 ((2)). 283-291
117. Gamo NJ, Wang M, Arnsted AF. Methylphenidate and atomoxetine enhance prefrontal function through a2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010 ; 49 ((10)). 1011-1023
118. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention-deficit/hyperactivity disorder. Arch Dis Child. 2005 ; 90 ((suppl 1)). i26 - i29
119. Parraga HC, Parraga MI, Harris DK. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med. 2007 ; 37 ((4)). 415-424
120. Sears J, Patel NC. Development of tics in a thirteen-year old male following atomoxetine use. CNS Spectr. 2008 ; 13 ((4)). 301-303
121. Ledbetter M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol. 2005 ; 15 ((2)). 331-333
122. Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008 ; 18 ((2)). 79-86
123. Erdogan A, Ozcay F, Piskin E, et al. Idiosyncratic liver failure probably associated with atomoxetine: a case report. J Child Adolesc Psychopharmacol. 2011 ; 21 ((3)). 295-297
124. Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 2008 ; 31 ((4)). 345-354
125. Lim JR, Faught PR, Chalasani NP, et al. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006 ; 148 ((6)). 831-834
126. Camporeale A, Day KA, Ruff D, et al. Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis. Drug Saf. 2013 ; 36 ((8)). 663-671
127. Lilly. Package insert Strattera. http://pi.lilly.com/us/strattera-pi.pdf. Accessed October 26, 2013.
128. Bushe CJ, Savill NC. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. Child Adolesc Psychiatry Ment Health. 2013 ; 7 ((1)). 19
129. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998 ; 155 ((5)). 693-695
130. Faraone SV, Wigal SB, Hodgkins P. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J Atten Disord. 2007 ; 11 ((1)). 74-82
131. Dittman RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013 ; 27 ((12)). 1081-1092
132. Centerwatch. http://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=1053. Accessed October 21, 2013.
133. Package Insert Intuiv. http://pi.shirecontent.com/PI/PDFs/Intuniv-USA-ENG.pdf. Accessed October 26, 2013.
134. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 ; 34 ((1)). 50-54
135. Cruz MP. Guanfacine extended-release tablets (Intuniv), a nonstimulant selective alphaaa-adrenergic receptor agonist for attention-deficit/hyperactivity disorder. P T. 2010 ; 35 ((8)). 448-451
136. Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat. 2008 ; 4 ((3)). 499-506
137. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999 ; 38 ((12)). 1551-1559
138. Wilens TE, Spencer TJ, Swanson JM, et al. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry. 1999 ; 38 ((5)). 614-619
139. Goldberg J. Clonidine and methylphenidate were effective for attention deficit hyperactivity disorder in children with comorbid tics. Evid Based Ment Health. 2002 ; 5 ((4)). 122
140. Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003 ; 42 ((8)). 886-894
141. Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1994 ; 33 ((3)). 424-426
142. Ghanizadeh A. Insomnia, night terror, and depression related to clonidine in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008 ; 28 ((6)). 725-726
143. Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004 ; 6 ((4)). 159-166
144. Jafarinia M, Mohammadi MR, Ashrafi M, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol. 2012 ; 27 ((4)). 411-418
145. Maneeton N, Maneeton B, Srisurapanont M, et al. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011 ; 65 ((7)). 611-617
146. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995 ; 34 ((5)). 649-657
147. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001 ; 13 ((3)). 129-134
148. Beyens MN, Guy C, Mounier G, et al. Serious adverse reactions of bupropion for smoking cessation: analysis of the French pharmacovigilence database from 2001 to 2004. Drug Saf. 2008 ; 31 ((11)). 1017-1026
149. GSK. Package insert bupropion. http://www.gsksource.com/gskprm/htdocs/documents/WELLBUTRIN-TABLETS-PI-MG.PDF. Accessed October 26, 2013.
150. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006 ; 6 ((9)). 1249-1265
151. Spencer T, Biederman J, Steingard R, et al. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1993 ; 32 ((1)). 211-214
152. Prince JB, Wilens TE, Biederman J, et al. A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Pscyhopharmacol. 2000 ; 10 ((3)). 193-204
153. Ghanizadeh A. A systematic review of the efficacy and safety of desipramine for treating ADHD. Curr Drug Saf. 2013 ; 8 ((3)). 169-174
154. Ghanizadeh A, Freeman RD, Berk M. Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. Rev Recent Clin Trials. 2013 ; 8 ((1)). 2-8
155. Rubinstein S, Malone MA, Roberts W, et al. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006 ; 16 ((4)). 404-415
156. Levin GM. Attention-deficit hyperactivity disorder: the pharmacist's role. Am Pharm. 1995 ; NS35 (11). 10-20
157. Galanter CA, Leibenuft E. Frontiers between attention deficit hyperactivity disorder and bipolar disorder. Child Adolesc Psychiatry Clin N Amer. 2008 ; 17 ((2)). 325-346
158. Horrigan JP, Barnhill LJ. Guanfacine and secondary mania in children. J Affect Disord. 1999 ; 54 ((3)). 309-314
159. Bahali K, Uneri OS, Ipek H. Atomoxetine-induced mania-like symptoms in an adolescent patient. Actas Esp Psiquiatr. 2013 ; 41 ((2)). 137-138
160. Aggarwal A, Sharma RC. Bupropion-induced mania and hypomania: a report of two cases. J Neuropsychiatry Clin Neurosci. 2011 ; 23 ((2)). E51 - E52
161. BarkelyR. ADHD rating Scales. Additude. http://www.additudemag.com/adhd/article/8013.html. Accessed October 24, 2013.
162. The ADD/ADHD Support Site. http://www.attentiondeficit-add-adhd.com/adhd-connors-test.htm. Accessed October 24, 2013.